Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus

The American Journal of Cardiology
Jeffrey S Borer, Jean-Claude Tardif

Abstract

Ivabradine is a specific heart rate-lowering antianginal agent that was evaluated in a clinical development program involving approximately 3,000 patients with stable coronary artery disease, most with angina pectoris. We analyzed the pharmacokinetics, efficacy (evaluated by exercise tolerance testing), safety, and effects on glucose metabolism of ivabradine in patients with diabetes mellitus (DM) in this program. Most analyses included data from 535 patients with DM, approximately 18% of the overall patient sample. Patients with DM were older, more likely to be women, and more likely to have more severe angina pectoris than patients without DM. The pharmacokinetics of ivabradine did not differ in patients with DM versus those without DM. A reduction in the heart rate at rest with ivabradine was similar in those with (15.2%) and without (15.7%) DM. At baseline, the exercise capacity tended to be lower in the patients with DM, but the improvements in most exercise tolerance measures with ivabradine treatment were similar in patients with and without DM. No special safety concerns were associated with ivabradine in those with DM. The rates of sinus bradycardia and visual disturbances, known to be related to the action of ivabradi...Continue Reading

References

Nov 1, 1990·Journal of the American College of Cardiology·K RanjadayalanA D Timmis
Mar 1, 2005·Diabetes Care·Emily B SchroederUNKNOWN Atherosclerosis Risk in Communities (ARIC) study
Oct 11, 2005·European Heart Journal·Jean-Claude TardifUNKNOWN INITIATIVE Investigators
Nov 1, 2005·Expert Opinion on Drug Safety·Hassane IzzedineGilbert Deray
Jan 18, 2006·BMJ : British Medical Journal·Caroline A DalyUNKNOWN Euro Heart Survey Investigators
Mar 8, 2006·The Canadian Journal of Cardiology·David F Blackburn, Thomas W Wilson
Apr 28, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dario DiFrancesco
Aug 29, 2006·Diabetes Care·K M Venkat NarayanTheodore J Thompson
Jun 5, 2007·Journal of Molecular and Cellular Cardiology·Annalisa BucchiDario DiFrancesco
Oct 26, 2007·Diabetes Care·Mercedes R CarnethonMartha L Daviglus

❮ Previous
Next ❯

Citations

Apr 27, 2010·Advances in Therapy·Graziano Riccioni
Jan 25, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Benjamin LauzierChristine Des Rosiers
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Neeraj Parakh, Balram Bhargava
Feb 26, 2016·Hospital Pharmacy·Dennis J CadaDanial E Baker
Nov 22, 2011·Expert Opinion on Pharmacotherapy·Antonio Arrebola-MorenoJuan-Carlos Kaski
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Graziano Riccioni
Aug 1, 2016·Cardiovascular Drugs and Therapy·Alessandra Giavarini, Ranil de Silva
May 20, 2015·JAAPA : Official Journal of the American Academy of Physician Assistants·Deepali Dixit, Katarzyna Kimborowicz
Nov 20, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Graziano Riccioni
Jan 1, 2015·The Open Cardiovascular Medicine Journal·Marco Picichè
Jun 7, 2019·Circulation·Shannon M DunlayUNKNOWN American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Car
Sep 29, 2017·Science Translational Medicine·Christoforos TsantoulasPeter A McNaughton
Mar 2, 2021·Frontiers in Cardiovascular Medicine·Fedor Simko, Tomas Baka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.